Capricor shares surged over 440% after its cell therapy Deramiocel met primary and key secondary endpoints in the pivotal HOPE-3 Phase 3 trial for Duchenne muscular dystrophy. The 12-month, placebo-controlled study of 106 participants showed meaningful improvements in muscle and heart function, with most patients already showing cardiomyopathy at baseline.